Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

A better knowledge of the complex interactions between cancer cells and the immune
system has led to novel immunotherapy approaches. Treatment with selective anti-PD1, anti …

Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically
been notable worldwide and many attempts have been made to raise the overall survival of …

Colorectal cancer (CRC) is one of the most common cancers worldwide. Current therapies
such as surgery, chemotherapy, and radiotherapy encounter obstacles in preventing …

The outcomes of multiple myeloma (MM) have been improved significantly with the
therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal …

With the recent US Food and Drug Administration approvals of pembrolizumab and
nivolumab for refractory deficient mismatch repair metastatic colorectal cancer, immune …

Immunotherapy, particularly those based on immune checkpoint inhibitors (ICIs), has
become a useful approach for many neoplastic diseases. Despite the improvements of ICIs …

Cancer immunity is regulated by several mechanisms that include co-stimulatory and/or co-
inhibitory molecules known as immune checkpoints expressed by the immune cells. In …

There are increasing incidences and mortality rates for colorectal cancer in the world. It is
common for chemotherapy and radiation given to patients with colorectal cancer to cause …

The success of immune checkpoint inhibitors (ICIs) in an increasing range of heavily
mutated tumor types such as melanoma has culminated in their exploration in different …